https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 The risk of secondary progressive multiple sclerosis is geographically determined but modifiable https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54611 Wed 06 Mar 2024 10:38:32 AEDT ]]> Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52624 Thu 19 Oct 2023 14:15:33 AEDT ]]> Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52249 Thu 05 Oct 2023 14:07:20 AEDT ]]> Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50986 Mon 14 Aug 2023 15:59:28 AEST ]]> Predictors of treatment switching in the Big Multiple Sclerosis Data Network https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54767 Mon 11 Mar 2024 15:00:30 AEDT ]]> Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53931 Fri 22 Mar 2024 08:23:10 AEDT ]]> Disability accrual in primary and secondary progressive multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51685 Fri 15 Sep 2023 09:36:29 AEST ]]>